| Year |
Citation |
Score |
| 2018 |
Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, et al. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene. PMID 30478448 DOI: 10.1038/S41388-018-0567-7 |
0.321 |
|
| 2009 |
Robinson BW, Song Y, Germano G, Ernst P, Abrams J, Scott M, Kugath A, Helfrich M, Sunyer JO, Rhodes J, Balice-Gordon R, Felix CA. Zebrafish Mll Depletion Model Phenocopies Mammalian Mll Depletion and Implicates MLL as Master Regulator of Novel Developmental Hematopoietic Targets. Blood. 114: 3655-3655. DOI: 10.1182/Blood.V114.22.3655.3655 |
0.306 |
|
| 2008 |
Robinson BW, Behling KC, Gupta M, Zhang AY, Moore JS, Bantly AD, Willman CL, Carroll AJ, Adamson PC, Barrett JS, Felix CA. Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. British Journal of Haematology. 141: 827-39. PMID 18422996 DOI: 10.1111/j.1365-2141.2008.07100.x |
0.388 |
|
| 2008 |
Robinson BW, Cheung NK, Kolaris CP, Jhanwar SC, Choi JK, Osheroff N, Felix CA. Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. Blood. 111: 3802-12. PMID 18195096 DOI: 10.1182/Blood-2007-07-096065 |
0.318 |
|
| 2008 |
Zhang AY, Robinson BW, Wang L, Kao K, Cory L, Barrett JS, Atlas S, Chen I, Harvey RC, Willman CL, Devidas M, Carroll AJ, Hunger SP, Moore JS, Thompson CB, et al. Pan-Anti-Apoptotic BCL-2 Family Inhibitor, Obatoclax, Activates Autophagic Cell Death Pathway and Has Potent Cytotoxicity in Infant and Pediatric MLL-Rearranged Leukemias Blood. 112: 2647-2647. DOI: 10.1182/Blood.V112.11.2647.2647 |
0.375 |
|
| 2007 |
Flanagan SA, Robinson BW, Krokosky CM, Shewach DS. Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers. Molecular Cancer Therapeutics. 6: 1858-68. PMID 17575114 DOI: 10.1158/1535-7163.Mct-07-0068 |
0.677 |
|
| 2005 |
Rege JM, Robinson BW, Gupta M, Barrett JS, Adamson PC, Behling KC, Bantly AD, Moore JS, Felix CA. Pan-BCL-2 Family Small Molecule Inhibitor GX015-070 (GeminX, Inc.) Exhibits Single Agent Cytotoxicity, Is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations. Blood. 106: 3368-3368. DOI: 10.1182/blood.V106.11.3368.3368 |
0.338 |
|
| 2005 |
Robinson BW, Behling KC, Barrett JS, Gupta M, Rege JM, Moore JS, Bantly AD, Kim J, Hii G, Willman CL, Potter J, Adamson PC, Felix CA. Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound GenasenseTM (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations. Blood. 106: 3360-3360. DOI: 10.1182/Blood.V106.11.3360.3360 |
0.397 |
|
| 2004 |
Robinson BW, Ostruszka L, Im MM, Shewach DS. Promising combination therapies with gemcitabine. Seminars in Oncology. 31: 2-12. PMID 15199526 DOI: 10.1053/J.Seminoncol.2004.03.021 |
0.456 |
|
| 2003 |
Robinson BW, Im MM, Ljungman M, Praz F, Shewach DS. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Research. 63: 6935-41. PMID 14583494 |
0.736 |
|
| 2002 |
Shewach DS, Murphy PJ, Robinson BW, Vuletich J, Boucher PD, Blobaum AL, Zerbe L, Secrist JA, Parker WB. Multi-log cytotoxicity of carbocyclic 2'-deoxyguanosine in HSV-TK-expressing human tumor cells. Human Gene Therapy. 13: 543-51. PMID 11874632 DOI: 10.1089/10430340252809838 |
0.676 |
|
| 2001 |
Robinson BW, Shewach DS. Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 2581-9. PMID 11489842 |
0.728 |
|
| Show low-probability matches. |